Published in Blood on April 16, 2008
Targeting natural killer cells and natural killer T cells in cancer. Nat Rev Immunol (2012) 3.43
Harnessing invariant NKT cells in vaccination strategies. Nat Rev Immunol (2009) 2.79
The role of NKT cells in tumor immunity. Adv Cancer Res (2008) 2.05
Type I natural killer T cells suppress tumors caused by p53 loss in mice. Blood (2009) 1.91
iNKT cell autoreactivity: what is 'self' and how is it recognized? Nat Rev Immunol (2010) 1.44
Oligoclonality and innate-like features in the TCR repertoire of type II NKT cells reactive to a beta-linked self-glycolipid. Proc Natl Acad Sci U S A (2010) 1.27
Cross-regulation between distinct natural killer T cell subsets influences immune response to self and foreign antigens. J Cell Physiol (2009) 1.20
NKT cell networks in the regulation of tumor immunity. Front Immunol (2014) 1.13
NKT cell adjuvant-based tumor vaccine for treatment of myc oncogene-driven mouse B-cell lymphoma. Blood (2012) 1.09
Anti-tumor potential of type-I NKT cells against CD1d-positive and CD1d-negative tumors in humans. Clin Immunol (2010) 1.04
Abnormal changes in NKT cells, the IGF-1 axis, and liver pathology in an animal model of ALS. PLoS One (2011) 1.00
CD1d-expressing breast cancer cells modulate NKT cell-mediated antitumor immunity in a murine model of breast cancer metastasis. PLoS One (2011) 0.98
The regulatory role of invariant NKT cells in tumor immunity. Cancer Immunol Res (2015) 0.96
Developing understanding of the roles of CD1d-restricted T cell subsets in cancer: reversing tumor-induced defects. Clin Immunol (2011) 0.95
The immunoregulatory role of type I and type II NKT cells in cancer and other diseases. Cancer Immunol Immunother (2014) 0.93
Altered development of NKT cells, γδ T cells, CD8 T cells and NK cells in a PLZF deficient patient. PLoS One (2011) 0.92
iNKT cells control mouse spontaneous carcinoma independently of tumor-specific cytotoxic T cells. PLoS One (2010) 0.91
Tuberous sclerosis 1 promotes invariant NKT cell anergy and inhibits invariant NKT cell-mediated antitumor immunity. J Immunol (2014) 0.91
A threonine-based targeting signal in the human CD1d cytoplasmic tail controls its functional expression. J Immunol (2010) 0.90
The Extended Family of CD1d-Restricted NKT Cells: Sifting through a Mixed Bag of TCRs, Antigens, and Functions. Front Immunol (2015) 0.89
CD1d activation and blockade: a new antitumor strategy. J Immunol (2009) 0.87
Invariant NKT cells as novel targets for immunotherapy in solid tumors. Clin Dev Immunol (2012) 0.86
iNKT cells suppress the CD8+ T cell response to a murine Burkitt's-like B cell lymphoma. PLoS One (2012) 0.85
Adoptive immunotherapy mediated by ex vivo expanded natural killer T cells against CD1d-expressing lymphoid neoplasms. Haematologica (2009) 0.83
Invariant natural killer T cell-natural killer cell interactions dictate transplantation outcome after alpha-galactosylceramide administration. Blood (2009) 0.82
Lymphoma: immune evasion strategies. Cancers (Basel) (2015) 0.82
Regulation of NKT Cell Localization in Homeostasis and Infection. Front Immunol (2015) 0.81
Functional invariant NKT cells in pig lungs regulate the airway hyperreactivity: a potential animal model. J Clin Immunol (2010) 0.81
Type II NKT Cells in Inflammation, Autoimmunity, Microbial Immunity, and Cancer. Front Immunol (2015) 0.81
Cancer immunotherapy: Re-programming cells of the innate and adaptive immune systems. Oncoimmunology (2012) 0.80
mTOR and its tight regulation for iNKT cell development and effector function. Mol Immunol (2015) 0.80
Mouse Invariant Monoclonal Antibody NKT14: A Novel Tool to Manipulate iNKT Cell Function In Vivo. PLoS One (2015) 0.80
A push-pull vaccine strategy using Toll-like receptor ligands, IL-15, and blockade of negative regulation to improve the quality and quantity of T cell immune responses. Vaccine (2011) 0.80
NKT cell adjuvants in therapeutic vaccines against hematological cancers. Oncoimmunology (2013) 0.79
A Thr/Ser dual residue motif in the cytoplasmic tail of human CD1d is important for the down-regulation of antigen presentation following a herpes simplex virus 1 infection. Immunology (2013) 0.79
Natural killer T cells subsets in cancer, functional defects in prostate cancer and implications for immunotherapy. Cancers (Basel) (2011) 0.79
CD1d expression on and regulation of murine hematopoietic stem and progenitor cells. Blood (2012) 0.79
iNKT cell cytotoxic responses control T-lymphoma growth in vitro and in vivo . Cancer Immunol Res (2014) 0.79
CD1d-antibody fusion proteins target iNKT cells to the tumor and trigger long-term therapeutic responses. Cancer Immunol Immunother (2012) 0.78
Natural killer T cell based Immunotherapy. J Vaccines Vaccin (2012) 0.77
Role and regulation of CD1d in normal and pathological B cells. J Immunol (2014) 0.77
NKT Cell Responses to B Cell Lymphoma. Med Sci (Basel) (2014) 0.77
Critical role of NKT cells in posttransplant alloantibody production. Am J Transplant (2014) 0.76
Type II NKT cells: a distinct CD1d-restricted immune regulatory NKT cell subset. Immunogenetics (2016) 0.76
The adaptor protein SAP regulates type II NKT-cell development, cytokine production, and cytotoxicity against lymphoma. Eur J Immunol (2014) 0.76
Dynamics of NKT-Cell Responses to Chlamydial Infection. Front Immunol (2015) 0.76
CD8⁺ T Cell-Independent Immune-Mediated Mechanisms of Anti-Tumor Activity. Crit Rev Immunol (2015) 0.75
Type II NKT Cells and Their Emerging Role in Health and Disease. J Immunol (2017) 0.75
Invariant natural killer T cells in hematopoietic stem cell transplantation: killer choice for natural suppression. Bone Marrow Transplant (2016) 0.75
Combination of glycosphingosomes and liposomal doxorubicin shows increased activity against dimethyl-α-benzanthracene-induced fibrosarcoma in mice. Int J Nanomedicine (2015) 0.75
Tailored design of NKT-stimulatory glycolipids for polarization of immune responses. J Biomed Sci (2017) 0.75
Does an NKT-cell-based immunotherapeutic approach have a future in multiple myeloma? Oncotarget (2016) 0.75
Inflammation and cancer. Nature (2002) 53.78
The biology of NKT cells. Annu Rev Immunol (2007) 14.43
In search of the 'missing self': MHC molecules and NK cell recognition. Immunol Today (1990) 10.84
Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature (1986) 9.73
Requirement for Valpha14 NKT cells in IL-12-mediated rejection of tumors. Science (1997) 8.95
Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell (2004) 7.61
An invariant T cell receptor alpha chain is used by a unique subset of major histocompatibility complex class I-specific CD4+ and CD4-8- T cells in mice and humans. J Exp Med (1994) 7.35
Cutting edge: Cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J Immunol (1999) 5.86
CD1 recognition by mouse NK1+ T lymphocytes. Science (1995) 5.33
NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat Immunol (2000) 4.75
CD1d1 mutant mice are deficient in natural T cells that promptly produce IL-4. Immunity (1997) 4.54
Differential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med (2000) 4.45
Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining. J Exp Med (2002) 4.34
The CD1 system: antigen-presenting molecules for T cell recognition of lipids and glycolipids. Annu Rev Immunol (1999) 4.10
Distinct functional lineages of human V(alpha)24 natural killer T cells. J Exp Med (2002) 3.70
Selective induction of NK cell proliferation and cytotoxicity by activated NKT cells. Eur J Immunol (2000) 2.99
Differential antitumor immunity mediated by NKT cell subsets in vivo. J Exp Med (2005) 2.83
Derangement of immune responses by myeloid suppressor cells. Cancer Immunol Immunother (2003) 2.65
Cell wall glycosphingolipids of Sphingomonas paucimobilis are CD1d-specific ligands for NKT cells. Eur J Immunol (2005) 2.54
A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma. J Exp Med (2003) 2.48
The human liver contains multiple populations of NK cells, T cells, and CD3+CD56+ natural T cells with distinct cytotoxic activities and Th1, Th2, and Th0 cytokine secretion patterns. J Immunol (1999) 2.39
A nonclassical non-Valpha14Jalpha18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance. J Exp Med (2005) 2.32
Cross-presentation of disialoganglioside GD3 to natural killer T cells. J Exp Med (2003) 2.30
Human CD1d-glycolipid tetramers generated by in vitro oxidative refolding chromatography. Proc Natl Acad Sci U S A (2001) 1.99
CD1d ligands: the good, the bad, and the ugly. J Immunol (2006) 1.89
Type II NKT cell-mediated anergy induction in type I NKT cells prevents inflammatory liver disease. J Clin Invest (2007) 1.83
The anti-tumor activity of IL-12: mechanisms of innate immunity that are model and dose dependent. J Immunol (2000) 1.82
Quantitation and phenotypic analysis of natural killer T cells in primary biliary cirrhosis using a human CD1d tetramer. Gastroenterology (2002) 1.72
Functionally distinct NKT cell subsets and subtypes. J Exp Med (2005) 1.54
NKT cells and tumor immunity--a double-edged sword. Nat Immunol (2000) 1.53
Recycling CD1d1 molecules present endogenous antigens processed in an endocytic compartment to NKT cells. J Immunol (2002) 1.51
Cross-presentation of glycolipid from tumor cells loaded with alpha-galactosylceramide leads to potent and long-lived T cell mediated immunity via dendritic cells. J Exp Med (2007) 1.40
Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer. J Exp Med (2005) 1.35
Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells. Leukemia (2003) 1.28
Natural killer T (NKT) cells and their role in antitumor immunity. Crit Rev Oncol Hematol (2002) 1.27
CD44 and its partners in metastasis. Clin Exp Metastasis (2003) 1.27
Inhibition of glycolipid shedding rescues recognition of a CD1+ T cell lymphoma by natural killer T (NKT) cells. Proc Natl Acad Sci U S A (2002) 1.25
Selective loss of natural killer T cells by apoptosis following infection with lymphocytic choriomeningitis virus. J Virol (2001) 1.23
Valpha14 NK T cell-triggered IFN-gamma production by Gr-1+CD11b+ cells mediates early graft loss of syngeneic transplanted islets. J Exp Med (2005) 1.22
Critical proinflammatory and anti-inflammatory functions of different subsets of CD1d-restricted natural killer T cells during Trypanosoma cruzi infection. Infect Immun (2005) 1.17
Invariant natural killer T cells are preserved in patients with glioma and exhibit antitumor lytic activity following dendritic cell-mediated expansion. Int J Cancer (2004) 1.13
Invariant and noninvariant natural killer T cells exert opposite regulatory functions on the immune response during murine schistosomiasis. Infect Immun (2007) 1.12
Inhibition of early tumor growth requires J alpha 18-positive (natural killer T) cells. Cancer Res (2003) 1.09
Inhibition of antitumor immunity by invariant natural killer T cells in a T-cell lymphoma model in vivo. Int J Cancer (2006) 1.02
Working with NKT cells--pitfalls and practicalities. Curr Opin Immunol (2005) 0.99
Natural killer T cell-mediated antitumor immune responses and their clinical applications. Cancer Sci (2006) 0.98
Hyporesponsiveness to natural killer T-cell ligand alpha-galactosylceramide in cancer-bearing state mediated by CD11b+ Gr-1+ cells producing nitric oxide. Cancer Res (2006) 0.96
Non-Hodgkin's lymphoma in children and adolescents. Curr Oncol Rep (2006) 0.94
CD1d-mediated antigen presentation to natural killer T (NKT) cells. Crit Rev Immunol (2003) 0.93
Current status of immunotherapy in B cell malignancies. Curr Drug Targets (2006) 0.89
CD1d expression level in tumor cells is an important determinant for anti-tumor immunity by natural killer T cells. Leuk Lymphoma (2006) 0.87
Immunologic approaches to acute leukemia in the elderly. Semin Hematol (2006) 0.81
Periodontopathic bacterial endotoxin-induced tumor necrosis factor alpha production was inhibited by exercise in mice. FEMS Immunol Med Microbiol (2006) 0.77
Classification performance of instantaneous wave-free ratio (iFR) and fractional flow reserve in a clinical population of intermediate coronary stenoses: results of the ADVISE registry. EuroIntervention (2013) 4.30
Cell wall glycosphingolipids of Sphingomonas paucimobilis are CD1d-specific ligands for NKT cells. Eur J Immunol (2005) 2.54
Lamp-2a facilitates MHC class II presentation of cytoplasmic antigens. Immunity (2005) 2.40
Hybrid iFR-FFR decision-making strategy: implications for enhancing universal adoption of physiology-guided coronary revascularisation. EuroIntervention (2013) 2.15
Defective presentation of the CD1d1-restricted natural Va14Ja18 NKT lymphocyte antigen caused by beta-D-glucosylceramide synthase deficiency. Proc Natl Acad Sci U S A (2003) 1.80
Evidence for immune responses to a self-antigen in lung transplantation: role of type V collagen-specific T cells in the pathogenesis of lung allograft rejection. J Immunol (2002) 1.68
Recycling CD1d1 molecules present endogenous antigens processed in an endocytic compartment to NKT cells. J Immunol (2002) 1.51
Efficient, one-pot syntheses of biologically active alpha-linked glycolipids. Chem Commun (Camb) (2007) 1.34
Lipid protein interactions: the assembly of CD1d1 with cellular phospholipids occurs in the endoplasmic reticulum. J Immunol (2002) 1.33
Diagnostic classification of the instantaneous wave-free ratio is equivalent to fractional flow reserve and is not improved with adenosine administration. Results of CLARIFY (Classification Accuracy of Pressure-Only Ratios Against Indices Using Flow Study). J Am Coll Cardiol (2013) 1.26
Inhibition of glycolipid shedding rescues recognition of a CD1+ T cell lymphoma by natural killer T (NKT) cells. Proc Natl Acad Sci U S A (2002) 1.25
Myeloid marker expression on antiviral CD8+ T cells following an acute virus infection. Eur J Immunol (2003) 1.23
Efficient synthesis of alpha-galactosyl ceramide analogues using glycosyl iodide donors. Org Lett (2005) 1.22
Impaired cell surface expression of human CD1d by the formation of an HIV-1 Nef/CD1d complex. Virology (2005) 1.19
BATF transgenic mice reveal a role for activator protein-1 in NKT cell development. J Immunol (2003) 1.19
CD1d1-dependent control of the magnitude of an acute antiviral immune response. J Immunol (2004) 1.16
Thymic selection pathway regulates the effector function of CD4 T cells. J Exp Med (2007) 1.15
One-pot syntheses of immunostimulatory glycolipids. J Org Chem (2010) 1.13
Disruption of MHC class II-restricted antigen presentation by vaccinia virus. J Immunol (2005) 1.13
Ability to predict metastasis based on pathology findings and alterations in nuclear structure of normal-appearing and cancer peripheral zone epithelium in the prostate. Clin Cancer Res (2004) 1.12
Virus-induced inhibition of CD1d1-mediated antigen presentation: reciprocal regulation by p38 and ERK. J Immunol (2005) 1.10
Tc17 cells are capable of mediating immunity to vaccinia virus by acquisition of a cytotoxic phenotype. J Immunol (2010) 1.06
Inhibition of CD1d1-mediated antigen presentation by the vaccinia virus B1R and H5R molecules. Eur J Immunol (2006) 1.05
Vaccinia virus infection induces dendritic cell maturation but inhibits antigen presentation by MHC class II. Cell Immunol (2007) 1.05
Construction of di-scFv through a trivalent alkyne-azide 1,3-dipolar cycloaddition. Chem Commun (Camb) (2006) 1.05
A nanoengineering approach for investigation and regulation of protein immobilization. ACS Nano (2008) 1.02
Regulation of Th2 cytokine expression in NKT cells: unconventional use of Stat6, GATA-3, and NFAT2. J Immunol (2006) 1.02
Efficient synthesis of a C-analogue of the immunogenic bacterial glycolipid BbGL2. Org Lett (2006) 1.02
Inhibition of antitumor immunity by invariant natural killer T cells in a T-cell lymphoma model in vivo. Int J Cancer (2006) 1.02
Investigation into an efficient synthesis of 2,3-dehydro-N-acetyl neuraminic acid leads to three decarboxylated sialic acid dimers. Carbohydr Res (2008) 1.02
Quantitative measurements of recombinant HIV surface glycoprotein 120 binding to several glycosphingolipids expressed in planar supported lipid bilayers. J Am Chem Soc (2002) 1.01
Efficient route to 2-deoxy beta-O-aryl-d-glycosides via direct displacement of glycosyl iodides. Org Lett (2003) 1.00
Vesicular stomatitis virus matrix protein impairs CD1d-mediated antigen presentation through activation of the p38 MAPK pathway. J Virol (2008) 0.99
Synthesis and structural characterization of sialic acid-glutamic acid hybrid foldamers as conformational surrogates of alpha-2,8-linked polysialic acid. J Am Chem Soc (2009) 0.99
Vaccinia virus blocks Stat1-dependent and Stat1-independent gene expression induced by type I and type II interferons. J Interferon Cytokine Res (2008) 0.99
Long-term loss of canonical NKT cells following an acute virus infection. Eur J Immunol (2005) 0.99
Vinyl sulfones: synthetic preparations and medicinal chemistry applications. Med Res Rev (2006) 0.99
CD1d-expressing breast cancer cells modulate NKT cell-mediated antitumor immunity in a murine model of breast cancer metastasis. PLoS One (2011) 0.98
STAT3-dependent IL-21 production from T helper cells regulates hematopoietic progenitor cell homeostasis. Blood (2011) 0.97
Supramolecular copper hydroxide tennis balls: self-assembly, structures, and magnetic properties of octanuclear [Cu(8)L(8)(OH)(4)](4+) clusters (HL = N-(2-pyridylmethyl)acetamide). Inorg Chem (2004) 0.97
Mechanistic studies on the stereoselective formation of beta-mannosides from mannosyl iodides using alpha-deuterium kinetic isotope effects. J Org Chem (2007) 0.96
Regulation of the actin cytoskeleton by Rho kinase controls antigen presentation by CD1d. J Immunol (2012) 0.96
CD44 differentially activates mouse NK T cells and conventional T cells. J Immunol (2006) 0.94
Two-step synthesis of the immunogenic bacterial glycolipid BbGL1. Org Lett (2008) 0.93
Chemoenzymatic synthesis of cholesteryl-6-O-tetradecanoyl-α-D-glucopyranoside: a product of host cholesterol efflux promoted by Helicobacter pylori. Chem Commun (Camb) (2012) 0.92
Synthesis of oligomers derived from amide-linked neuraminic acid analogues. J Org Chem (2004) 0.92
Solution- and solid-phase oligosaccharide synthesis using glucosyl iodides: a comparative study. Carbohydr Res (2002) 0.92
An efferocytosis-induced, IL-4-dependent macrophage-iNKT cell circuit suppresses sterile inflammation and is defective in murine CGD. Blood (2013) 0.92
Human immunodeficiency virus gp120 downregulates CD1d cell surface expression. Immunol Lett (2004) 0.91
Reduction in CD1d expression on dendritic cells and macrophages by an acute virus infection. J Leukoc Biol (2004) 0.90
Selective acetylation of per-O-TMS-protected monosaccharides. Org Lett (2010) 0.90
A threonine-based targeting signal in the human CD1d cytoplasmic tail controls its functional expression. J Immunol (2010) 0.90
Protein kinase C delta is a critical regulator of CD1d-mediated antigen presentation. Eur J Immunol (2007) 0.89
Role of 4-1BB (CD137) in the functional activation of cord blood CD28(-)CD8(+) T cells. Blood (2002) 0.89
Synthesis of C-4 and C-7 triazole analogs of zanamivir as multivalent sialic acid containing scaffolds. Carbohydr Res (2007) 0.89
Significant variations in nuclear structure occur between and within Gleason grading patterns 3, 4, and 5 determined by digital image analysis. Prostate (2007) 0.88
Current developments in HIV chemotherapy. ChemMedChem (2006) 0.88
Non-natural glycosphingolipids and structurally simpler analogues bind HIV-1 recombinant Gp120. Bioorg Med Chem (2002) 0.88
The remarkable stability of chimeric, sialic acid-derived alpha/delta-peptides in human blood plasma. Chem Biol Drug Des (2010) 0.88
Synthesis and solid-state molecular structures of nitrosoalkane complexes of iron porphyrins containing methanol, pyridine, and 1-methylimidazole ligands. J Inorg Biochem (2004) 0.87
Chemotherapeutic interventions targeting HIV interactions with host-associated carbohydrates. Chem Rev (2007) 0.87
One-bead-one-inhibitor-one-substrate screening of neuraminidase activity. Chembiochem (2005) 0.87
1H and 13C NMR assignments and X-ray structures for three monocyclic benzoannelated dilactam polyethers. Magn Reson Chem (2006) 0.87
Three related benzoannelated diazapolyether macrocycles: effects of macrocycle ring size and position of benzo groups on hydrogen bonding of the amine H atoms. Acta Crystallogr C (2007) 0.87
A role for natural killer T cells and CD1d molecules in counteracting suppression of hematopoiesis in mice induced by infection with murine cytomegalovirus. Exp Hematol (2007) 0.86
Regioselective silyl/acetate exchange of disaccharides yields advanced glycosyl donor and acceptor precursors. J Org Chem (2013) 0.86
Perfluorocarbon-loaded Shell Crosslinked Knedel-like Nanoparticles: Lessons regarding polymer mobility and self assembly. J Polym Sci A Polym Chem (2009) 0.86
Synthesis and biological evaluation of geminal disulfones as HIV-1 integrase inhibitors. J Med Chem (2005) 0.85
Natural history of disease progression in patients who fail to achieve an undetectable prostate-specific antigen level after undergoing radical prostatectomy. Cancer (2004) 0.85
Solution phase conformation and proteolytic stability of amide-linked neuraminic Acid analogues. Biopolymers (2013) 0.85
Solution-phase hexasaccharide synthesis using glucosyl iodides. Org Lett (2002) 0.85
When is a bone scan study appropriate in asymptomatic men diagnosed with prostate cancer? Asian J Androl (2008) 0.84
Importance of N-linked glycosylation in the functional expression of murine CD1d1. Immunology (2007) 0.83
Discontinuum between a thiolate and a thiol ligand. Inorg Chem (2002) 0.83
Synthesis of highly pH-responsive glucose poly(orthoester). Angew Chem Int Ed Engl (2013) 0.83
Improvement in coronary haemodynamics after percutaneous coronary intervention: assessment using instantaneous wave-free ratio. Heart (2013) 0.83
Intermediate-term efficacy of Tm:YAG laser prostate vaporesection for bladder outlet obstruction: initial experience from a UK teaching hospital. Urol Int (2011) 0.82
A general chemical synthesis platform for crosslinking multivalent single chain variable fragments. Org Biomol Chem (2011) 0.82